OWLT.NYSEOwlet, INC

10-Q: Owlet Reports Revenue Surge Amidst Going Concern Warning

Sentiment:

Quarterly Report


Owlet, Inc. reported a 33.1% revenue increase for the first half of 2025 and improved operating loss, but faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.

Delay expectedWTI granted a 90-day extension for the Second Tranche Commitment of the WTI Loan Facility, making it available through November 13, 2025, which was previously available through August 15, 2025.
Capital raiseThe company issued 3,135,136 shares of common stock in September 2024, receiving net proceeds of $10.590 million.In February 2024, the company sold 9,250 shares of Series B convertible preferred stock and warrants for $9.250 million.The company entered into a WTI Loan Facility for up to $15.000 million, with $7.500 million drawn as of June 30, 2025, and a $5.000 million second tranche commitment extended to November 13, 2025.The company entered into an ABL Line of Credit for up to $15.000 million (increasing to $20.000 million on September 11, 2025), with $14.876 million outstanding as of June 30, 2025.On August 7, 2025, the company entered into an Exchange Agreement to exchange Series A and Series B Warrants for 5,426,429 newly issued common shares, subject to stockholder approval.The company explicitly states that it will likely need to raise additional capital in the future to execute its strategic plan and fund ongoing operations.
Worse than expectedThe company reported a significant net loss of $(34.622) million for the six months ended June 30, 2025, compared to a net income of $2.127 million in the prior year period. This was primarily driven by a large non-cash common stock warrant liability adjustment of $(28.066) million.The company explicitly states that recurring operating losses and negative cash flows from operations, coupled with a low cash balance relative to current obligations, raise substantial doubt about its ability to continue as a going concern within one year.

Summary

  • Revenues increased by 33.1% to $47.167 million for the six months ended June 30, 2025, compared to $35.449 million in the prior year period.
  • Gross profit rose to $24.706 million for the first half of 2025, up from $16.799 million in the same period last year, with gross margin improving to 52.4% from 47.4%.
  • Operating loss improved to $(4.590) million for the six months ended June 30, 2025, compared to $(7.990) million in the prior year period.
  • Net loss significantly increased to $(34.622) million for the six months ended June 30, 2025, primarily due to a $(28.066) million common stock warrant liability adjustment, compared to a net income of $2.127 million in the prior year.
  • The company reported an accumulated deficit of $(302.817) million as of June 30, 2025, and negative cash flows from operations of $(8.170) million for the six months ended June 30, 2025.
  • As of June 30, 2025, cash and cash equivalents stood at $21.827 million.
  • One customer accounted for 64% of net revenues for the three months ended June 30, 2025, and 52% for the six months ended June 30, 2025, also representing 68% of accounts receivable as of June 30, 2025.
  • The company has identified material weaknesses in its internal control over financial reporting, though one related to accrued sales tax was remediated as of June 30, 2025.

Sentiment

Score: 4

Explanation: While the company shows strong revenue growth and improved operating performance, the significant net loss (driven by non-cash warrant adjustments), persistent going concern warning, and multiple material weaknesses in internal controls present substantial financial and operational risks. The need for ongoing capital raises and high customer concentration further weigh on sentiment.

Positives

  • Revenue increased by 33.1% for the six months ended June 30, 2025, driven by higher sales of Dream Sock and Dream Duo products and the launch of the Owlet360 subscription service.
  • Gross margin improved to 52.4% for the first half of 2025, attributed to higher revenue, favorable product mix, improved fixed cost absorption, and lower direct product and fulfillment costs.
  • Operating loss decreased to $(4.590) million for the six months ended June 30, 2025, indicating improved operational efficiency before non-operating items.
  • A material weakness in internal control over financial reporting related to the completeness and accuracy of accrued sales tax has been remediated as of June 30, 2025.

Negatives

  • The company reported a significant net loss of $(34.622) million for the six months ended June 30, 2025, primarily due to a large non-cash common stock warrant liability adjustment.
  • Recurring operating losses and negative cash flows from operations since inception, resulting in an accumulated deficit of $(302.817) million as of June 30, 2025.
  • Substantial doubt exists about the company's ability to continue as a going concern within one year.
  • Net cash used in operating activities increased to $(8.170) million for the six months ended June 30, 2025, compared to $(6.721) million in the prior year.
  • Net interest expense significantly increased to $(1.970) million for the six months ended June 30, 2025, due to new loan facilities.
  • High customer concentration, with one customer accounting for 64% of Q2 2025 net revenues and 68% of accounts receivable.
  • Multiple material weaknesses in internal control over financial reporting persist, including insufficient personnel, ineffective segregation of duties, and issues with accounting for inventory, accrued liabilities, debt/equity arrangements, sales returns, cash flows, and IT general controls.

Risks

  • Limited operating history and continued operating losses, which could materially and adversely affect business, financial condition, and ability to continue as a going concern.
  • Fluctuations in business growth and potential failure to manage growth effectively.
  • Risk of governmental authorities or notified bodies requiring marketing authorization or similar certification for products, leading to regulatory enforcement actions, cessation of sales, or recalls.
  • Reliance on mobile applications and third-party app stores (Apple's App Store, Google Play Store) for distribution.
  • Substantial portion of sales comes from a limited number of retailers.
  • Requirement to obtain and maintain marketing authorizations or certifications from the FDA, foreign regulatory authorities, or notified bodies for medical device products.
  • Reliance on single manufacturers for assembly of Dream Sock, Smart Sock, BabySat, and Owlet Cam products, posing risks of manufacturing problems, delays, or increased costs.
  • Dependence on proprietary technology and the risk of inability to obtain, maintain, or successfully enforce intellectual property rights.
  • Business and operations may suffer from IT system failures, cyberattacks, or cybersecurity deficiencies.
  • Development, maintenance, and use of artificial intelligence technologies may not be beneficial, leading to poor product performance, reputational damage, or legal liability.
  • Increases in tariffs, trade restrictions, or taxes on products could adversely impact operations and profitability.
  • Involvement in disputes and other legal or regulatory proceedings that, if adversely decided or settled, could materially and adversely affect business.
  • Risk of product liability claims and potentially inadequate insurance coverage.
  • Exposure to additional business, political, regulatory, operational, financial, and economic risks from international market operations.
  • Success depends substantially on reputation and brand.
  • Some products are in development or recently introduced and may not achieve market acceptance.
  • Need to raise additional capital in the future, which may not be available on acceptable terms or at all, leading to significant dilution for existing stockholders.
  • Changes in tax laws, including the OBBBA, may impact future financial position and results of operations.
  • Broader macroeconomic impact of tariffs, such as inflation and reduced consumer purchasing power, could decrease demand for products.

Future Outlook

The company anticipates continued fluctuations in business growth and will need to raise additional capital in the future to execute its strategic plan, which may not be available on acceptable terms or at all. It is evaluating the impacts of the recently signed One Big Beautiful Bill Act of 2025 (OBBBA) on its financial position, including the reinstatement of 100% accelerated depreciation and immediate expensing of domestic research and development costs, both with retroactive application to early 2025.

Management Comments

  • Management has undertaken actions to address financial conditions, including recent equity and debt financings.
  • Management believes the unaudited condensed consolidated financial statements fairly present the financial position, results of operations, and cash flows.
  • Management is actively engaged in remediating identified material weaknesses in internal control over financial reporting, including hiring additional personnel and implementing new policies and controls.

Industry Context

The company operates in the digital parenting platform and infant care technology sector, with products like Dream Sock, Smart Sock, and BabySat. Its growth in revenues, particularly from Dream Sock and Dream Duo products, suggests increasing consumer demand within this niche. The launch of the Owlet360 subscription service indicates a strategic shift towards recurring revenue models, aligning with broader industry trends in connected health and subscription-based services. However, the reliance on a limited number of retailers and single manufacturers highlights supply chain and distribution vulnerabilities common in consumer electronics and medical device industries.

Comparison to Industry Standards

  • NA

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Amendment to Credit AgreementOn June 11, 2025, the company entered into a First Amendment to the Credit Agreement, modifying certain financial covenants (including EBITDA covenants), increasing capital expenditure limits, and expanding the eligibility of certain accounts receivable for borrowing.2025-06-11Aims to provide more flexibility under the ABL Line of Credit, potentially easing compliance with debt covenants and supporting capital investments.
Internal Control WeaknessesIdentified material weaknesses in internal control over financial reporting, including insufficient personnel, ineffective segregation of duties, and issues with accounting for inventory, accrued liabilities, debt/equity arrangements, sales returns, cash flows, and IT general controls. One material weakness related to accrued sales tax was remediated.2025-06-30These weaknesses indicate a risk of material misstatements in financial reporting and could impair access to capital markets. Remediation efforts are ongoing and will incur future costs.

Legal Proceedings

  • Butala v. Owlet, Inc. and Cherian v. Owlet, Inc. (securities class actions): Parties reached agreements in principle to settle Section 10(b) Claims for $3.500 million and Section 14(a) Claims for $1.750 million. Total $5.250 million recognized as general and administrative expense in 2024. Motions for preliminary approval are pending.
  • Janet Vargas, Derivatively on Behalf of Nominal Defendant Owlet, Inc. and Nathan Capleton, Derivatively on Behalf of Nominal Defendant Owlet, Inc. (derivative lawsuits): Consolidated into Vargas v. Workman, et al. Parties reached agreements in principle to settle, with $0.675 million recognized as general and administrative expense in Q1 2025. A motion for preliminary approval of the settlement was filed on April 9, 2025.

Stakeholder Impact

  • Shareholders: Face potential significant dilution from future equity issuances or the proposed warrant exchange. The going concern warning and material weaknesses in internal controls pose substantial risks to investment value.
  • Employees: Increased compensation expense and headcount suggest continued investment in human capital, but the company's financial instability could create uncertainty.
  • Customers: Increased sales of Dream Sock and Dream Duo products indicate strong demand, and the launch of Owlet360 subscription service aims to enhance customer experience and recurring revenue.
  • Creditors: The company's recurring losses and going concern warning increase credit risk, though it is currently in compliance with loan covenants. The ABL Line of Credit is collateralized by substantially all assets.
  • Suppliers: High customer concentration could impact the company's ability to manage supplier relationships and pricing, especially if demand from the largest customer fluctuates.

Next Steps

  • Seek stockholder approval for the warrant exchange agreement to issue 5,426,429 new common shares.
  • Continue remediation efforts for identified material weaknesses in internal control over financial reporting.
  • Evaluate the impact of the One Big Beautiful Bill Act of 2025 (OBBBA) on the company's financial statements.
  • Potentially draw on the remaining $5.000 million Second Tranche Commitment of the WTI Loan Facility by November 13, 2025.
  • Manage liquidity and potentially seek additional financing to support ongoing operations and strategic initiatives.

Key Dates

DateDescription
2020-09-17Closing of SBG initial public offering and sale of SBG Public Warrants and SBG Private Placement Warrants.
2021-07-15Completion of merger with Sandbridge Acquisition Corporation (SBG).
2021-11-01Filing of Butala v. Owlet, Inc. class action complaint.
2021-11-03Filing of Cherian v. Owlet, Inc. class action complaint.
2023-02-17Company entered into private placement investment agreements for Series A convertible preferred stock and Series A Warrants.
2023-03-27SVB Warrants granted to Silicon Valley Bank, expiring on March 27, 2035.
2023-09-08Court ruled to consolidate Butala and Cherian cases but maintain two distinct classes.
2023-11-21Amended complaints filed for each class in the Butala and Cherian cases.
2023-12-22Further amended consolidated filings in the Butala and Cherian cases.
2024-02-09Company filed motions to dismiss complaints in Butala and Cherian cases.
2024-02-25Company entered into private placement investment agreement for Series B convertible preferred stock and Series B Warrants.
2024-03-24Plaintiffs filed oppositions to motions to dismiss in Butala and Cherian cases.
2024-05-10Company filed replies in support of motions to dismiss in Butala and Cherian cases.
2024-06-11Company entered into a First Amendment to the Credit Agreement.
2024-06-30End of the current quarterly period.
2024-07-01Start of the period for which redeemable common stock was issued.
2024-08-01Date used for trailing 60-day volume-weighted average price for warrant valuation in Exchange Agreement.
2024-08-02Holders of Series A convertible preferred stock elected to convert shares.
2024-08-05Court denied Owlet's motions to dismiss Section 10(b) and Section 14(a) Claims in Butala/Cherian cases. Date of shares outstanding count.
2024-08-14Company filed registration statement on Form S-3 (File No. 333-281556).
2024-08-20Holders of Series A convertible preferred stock elected to convert shares.
2024-08-23Registration statement on Form S-3 declared effective.
2024-08-26Janet Vargas filed a derivative complaint on behalf of Owlet, Inc.
2024-09-01Start of the period for which redeemable common stock was issued.
2024-09-03End of the period for which redeemable common stock was issued.
2024-09-10Maturity Date of the ABL Line of Credit.
2024-09-11Company entered into underwriting agreement for common stock offering, Loan Facility Agreement with WTI, and Credit and Security Agreement for ABL Line of Credit. Titan Warrants issued. LSA with SVB terminated. Redeemable common stock issued to WTI Funds.
2024-09-12Start of the period for which redeemable common stock was issued.
2024-09-13Date of issuance of common stock and warrants in public stock offering.
2024-09-24Court entered a scheduling order in the Butala/Cherian case, setting trial for February 17, 2026.
2024-09-26Court granted Owlet's motion for reconsideration regarding Section 10(b) Claims and dismissed claims prior to merger.
2024-09-30End of availability for the first tranche of the WTI Loan Facility.
2024-10-01Start of the Second Tranche Condition Period for WTI Loan Facility. Start of period for WTI Loan Facility interest calculation.
2024-10-03Nathan Capleton filed a derivative complaint on behalf of Owlet, Inc.
2024-12-13Vargas and Capleton derivative complaints consolidated into Vargas v. Workman, et al.
2024-12-31End of fiscal year 2024. End of period for which three largest customers by total net accounts receivable were calculated.
2025-01-01Owlet360 subscription service launched. Effective date for ASU 2023-07 adoption. Retroactive application beginning for immediate expensing of domestic R&D costs under OBBBA.
2025-01-20Retroactive application beginning for 100% accelerated depreciation deductions on qualified property under OBBBA.
2025-01-31Plaintiffs filed motions seeking preliminary approval of settlements for Section 10(b) and Section 14(a) Claims in Butala action.
2025-02-07Plaintiffs filed an amended consolidated complaint in the Vargas action.
2025-03-01Date at which Series B convertible preferred stock becomes redeemable.
2025-03-03Parties in Vargas action filed a joint Notice of Settlement with the Court.
2025-03-06Court vacated deadlines in Vargas action in light of settlement notice.
2025-03-13Initial exercisable date for Titan Warrants.
2025-03-31Deadline for plaintiffs to file motion for preliminary approval of Vargas settlement (extended). 62,500 unvested shares of redeemable common stock forfeited.
2025-04-02Court ordered extension for Vargas settlement preliminary approval motion.
2025-04-09Plaintiffs filed motion for preliminary approval of the Vargas settlement.
2025-06-30End of the current quarterly period. Outstanding borrowings under ABL Line of Credit: $14,876k. Remaining borrowing base availability: $124k. Remaining principal balance on financed insurance premiums: $275k.
2025-07-04The One Big Beautiful Bill Act of 2025 (OBBBA) was signed into law.
2025-07-31End of period for which WTI granted a 90-day extension for the Second Tranche Commitment.
2025-08-07Company entered into a privately negotiated Exchange Agreement with certain warrant holders.
2025-08-08Date of filing of this 10-Q report.
2025-08-15Original availability end date for the Second Tranche Commitment of the WTI Loan Facility.
2025-08-18New deadline for submitting stockholder proposals for the 2025 Annual Meeting pursuant to Rule 14a-8.
2025-09-11ABL Line of Credit maximum principal amount increases to $20,000k.
2025-11-05Deadline for closing of the warrant Exchange Agreement, after which either party may terminate.
2025-11-13Extended availability end date for the Second Tranche Commitment of the WTI Loan Facility.
2025-12-31Effective date for expanded annual disclosures under ASU 2023-09.
2026-02-17Scheduled start date for trial in the Butala/Cherian securities class action.
2026-12-15Effective date for ASU 2024-03 (Disaggregation of Income Statement Expenses) for fiscal years beginning after this date.
2027-12-15Effective date for ASU 2024-03 (Disaggregation of Income Statement Expenses) for interim periods within fiscal years beginning after this date.
2028-02-17Series A convertible stock becomes redeemable and Series A Warrants expire.
2029-03-01Series B convertible preferred stock becomes redeemable.
2029-09-11Date the Redemption Option for redeemable common stock issued to WTI first becomes exercisable.
2035-03-27Expiration date for SVB Warrants.

Recommendation

hold

While Owlet, Inc. demonstrates strong revenue growth and improved gross margins, indicating positive market reception for its products, the company's financial health remains precarious. The explicit 'going concern' warning, significant accumulated deficit, and persistent material weaknesses in internal controls present substantial risks. The large net loss is primarily due to a non-cash warrant adjustment, which is less concerning for operational cash flow, but the underlying negative operating cash flow and reliance on financing are critical. The proposed warrant exchange could alleviate some liabilities but will result in shareholder dilution. Given the mixed signals – operational improvements versus severe liquidity and governance challenges – a 'hold' recommendation is appropriate. Investors should monitor the company's ability to secure additional financing, remediate internal control issues, and achieve sustained profitability before considering further investment.

Keywords

Owlet, baby monitoring, smart sock, infant care, health tech, consumer electronics, medical devices, SEC filing, 10-Q, quarterly report, financial results, going concern, warrant liability, internal controls, revenue growth, debt financing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.